Pluri Inc.
PLUR · XNASCIK 1158780fmd_0BH5GS03PVBW6E5YBA7E64SG0YManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jul 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | – | 0 | 0 | 0 | 1 | 1 |
| Cost of revenue | – | 0 | 0 | – | – | – | 0 | 0 | 1 | 1 |
| Gross profit | – | 0 | 0 | 0 | – | 0 | 0 | 0 | 1 | 0 |
| Research and development | 24 | 26 | 30 | 23 | 31 | 25 | 16 | 12 | 13 | 15 |
| Operating income | (28) | (34) | (36) | (29) | (51) | (42) | (27) | (22) | (22) | (25) |
| Interest expense | – | – | – | – | 0 | 1 | 1 | 1 | 1 | 1 |
| Interest and investment income | – | – | – | – | – | – | – | 1 | 1 | 0 |
| Other non-operating income (expense) | 0 | 8 | 0 | 0 | 1 | 0 | (2) | 1 | (1) | (0) |
| Income before taxes | – | – | – | – | – | – | – | (21) | (23) | (25) |
| Income tax expense | – | – | – | – | – | – | – | – | (0) | (0) |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (23) | (25) |
| Net income | (28) | (26) | (35) | (29) | (50) | (41) | (28) | (21) | (23) | (24) |
| Net income to common shareholders | – | – | – | 29 | 50 | 41 | 29 | 5,236 | 6,332 | 9,417 |